Trajan Scientific and Medical (Trajan) is pleased to announce that the Australian Research Council (ARC) has selected the University of Tasmania (UTAS) and Trajan’s proposal to create an ARC Training Centre for Portable Analytical Separation Technologies.
The program will see the Australian Government committing more than A$2.1 million funding from 2014 over three years, to establish and provide ongoing support to the Training Centre. The partnership of Trajan and UTAS combines industry knowledge and research to innovate in product design, development and manufacturing techniques.
The ARC’s Industrial Transformation Training Centres Scheme aims to foster close partnerships between university-based researchers and other research end-users to provide innovative Higher Degree by Research (HDR) and postdoctoral training for the end-user focused research industries vital to Australia's future.
Trajan encompasses a group of companies including SGE Analytical Science, Grale HDS and SciMed Precision with over 300 staff worldwide, and customers in over 100 countries.
Trajan’s focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements, especially those that can lead to portability, miniaturization and affordability.
Stephen Tomisich, Trajan’s Chief Executive Officer said, “Developing the new ARC Training Centre for Portable Analytical Separation Technologies with the University of Tasmania, is aligned with Trajan’s vision to engage in partnerships to deliver breakthrough solutions to the world.
“The Separation Science team at the University of Tasmania are world leaders and we are excited to be building our partnership with them.
“Our passion is to have a positive impact on the world of analytical and medical science; and this collaboration propels us towards that goal.”
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.